Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Smith & Nephew plc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 2.6× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days and Smith & Nephew plc for 121 Days on average.
| SJNK | SNN | |
|---|---|---|
Market Cap | $4.35B | $11.10B |
Volume | 3,211,044 | 1,051,703 |
Sector | Fixed Income | Health |
52-Week High | $25.57 | $37.17 |
52-Week Low | $24.13 | $26.42 |
Typical Hold Time | 41 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.21, showing minimal daily movement with a 0.04% gain. Technical indicators signal bearish momentum with moving averages heavily favoring selling pressure, though oscillators remain neutral. The ETF continues its dividend distribution pattern with recent payments of $0.14-$0.15 per share. Institutional activity shows mixed sentiment with Cetera Investment Advisers maintaining a $17.83 million position while Balefire LLC significantly reduced its holdings by 74.7% in recent quarters.
The ETF faces headwinds from bearish technical signals despite attractive yield comparisons to Treasury bonds. Current price consolidation near $24 support levels suggests cautious investor sentiment. Dividend consistency provides income appeal, but institutional selling pressure and technical weakness indicate near-term challenges for price appreciation amid competitive fixed-income alternatives.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
